MCID: CRD119
MIFTS: 67

Cardiac Arrest

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases

Aliases & Classifications for Cardiac Arrest

MalaCards integrated aliases for Cardiac Arrest:

Name: Cardiac Arrest 12 74 29 54 6 42 15 17 71 32
Cardiopulmonary Arrest 12 54 71
Circulatory Arrest 12 15 71
Heart Arrest 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0060319
ICD9CM 34 427.5
MeSH 43 D006323
SNOMED-CT 67 410429000 410430005
ICD10 32 I46 I46.0 I46.9
UMLS 71 C0018790 C0444720 C0600228

Summaries for Cardiac Arrest

MedlinePlus : 42 The heart has an internal electrical system that controls the rhythm of the heartbeat. Problems can cause abnormal heart rhythms, called arrhythmias. There are many types of arrhythmia. During an arrhythmia, the heart can beat too fast, too slow, or it can stop beating. Sudden cardiac arrest (SCA) occurs when the heart develops an arrhythmia that causes it to stop beating. This is different than a heart attack, where the heart usually continues to beat but blood flow to the heart is blocked. There are many possible causes of SCA. They include coronary heart disease, physical stress, and some inherited disorders. Sometimes there is no known cause for the SCA. Without medical attention, the person will die within a few minutes. People are less likely to die if they have early defibrillation. Defibrillation sends an electric shock to restore the heart rhythm to normal. You should give cardiopulmonary resuscitation (CPR) to a person having SCA until defibrillation can be done. If you have had an SCA, an implantable cardiac defibrillator (ICD) reduces the chance of dying from a second SCA. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Cardiac Arrest, also known as cardiopulmonary arrest, is related to post-cardiac arrest syndrome and ventricular fibrillation, paroxysmal familial, 1, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Cardiac Arrest is PLN (Phospholamban), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Cardiac conduction. The drugs Clonazepam and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and lung, and related phenotypes are cardiovascular system and muscle

Disease Ontology : 12 A congestive heart failure characterized by a sudden stop in effective blood circulation due to the failure of the heart to contract effectively or at all.

Wikipedia : 74 Cardiac arrest is a sudden loss of blood flow resulting from the failure of the heart to pump... more...

Related Diseases for Cardiac Arrest

Diseases in the Cardiac Arrest family:

Post-Cardiac Arrest Syndrome

Diseases related to Cardiac Arrest via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 851)
# Related Disease Score Top Affiliating Genes
1 post-cardiac arrest syndrome 35.0 S100B ENO2
2 ventricular fibrillation, paroxysmal familial, 1 33.8 TNNT2 SCN5A RYR2 DSP
3 jervell and lange-nielsen syndrome 1 33.5 SCN5A CASQ2 ANK2
4 short qt syndrome 33.2 SCN5A RYR2 CASQ2 ANK2
5 timothy syndrome 33.2 SCN5A RYR2 CASQ2 ANK2 AKAP9
6 cardiac conduction defect 33.1 SCN5A RYR2 PLN MYH7 MYBPC3 DSP
7 wolff-parkinson-white syndrome 33.1 TNNT2 SCN5A RYR2 MYH7 MYBPC3 CASQ2
8 malignant hyperthermia 33.1 TRDN SCN5A RYR2 MYH7 CASQ2
9 long qt syndrome 15 33.1 TRDN CALM1
10 long qt syndrome 14 33.1 SCN5A CALM1
11 arrhythmogenic right ventricular cardiomyopathy 33.0 SCN5A RYR2 PLN MYH7 DSP ANK2
12 long qt syndrome 32.9 TRDN SCN5A RYR2 MYH7 MYBPC3 DSP
13 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 32.9 TRDN SCN5A RYR2 MYH7 DSP CASQ2
14 ventricular tachycardia, catecholaminergic polymorphic, 3 32.9 RYR2 CASQ2
15 long qt syndrome 1 32.8 TRDN TNNT2 SCN5A RYR2 MYH7 MYBPC3
16 cardiac arrhythmia, ankyrin-b-related 32.8 SCN5A RYR2 ANK2 AKAP9
17 ventricular tachycardia, catecholaminergic polymorphic, 2 32.7 RYR2 CASQ2
18 catecholaminergic polymorphic ventricular tachycardia 32.7 TRDN TNNT2 SCN5A RYR2 MYH7 MYBPC3
19 progressive familial heart block 32.7 TNNT2 SCN5A DSP
20 brugada syndrome 32.7 TRDN TNNT2 SCN5A RYR2 PLN MYH7
21 myocardial infarction 32.6 TNNT2 SCN5A S100B MYH7 CYCS CKB
22 syncope 32.0 TNNT2 SCN5A RYR2
23 progressive familial heart block, type ia 31.7 SCN5A MYBPC3 ANK2
24 cardiac arrhythmia 31.6 SCN5A RYR2 ANK2 AKAP9
25 lipoprotein quantitative trait locus 31.6 TNNT2 SCN5A RYR2 ACE
26 head injury 31.5 S100B ENO2
27 atrioventricular block 31.5 SCN5A RYR2 MYH7 ACE
28 atrial standstill 1 31.4 TNNT2 SLC25A20 SCN5A RYR2 PLN MYH7
29 left bundle branch hemiblock 31.3 TNNT2 SCN5A RYR2 DSP ACE
30 congestive heart failure 31.3 TNNT2 SCN5A RYR2 PLN MYH7 MYBPC3
31 hypertrophic cardiomyopathy 31.2 TNNT2 SCN5A RYR2 PLN MYH7 MYBPC3
32 heart disease 31.0 TNNT2 SCN5A S100B RYR2 MYH7 MYBPC3
33 mitral valve insufficiency 31.0 TNNT2 MYBPC3 CKB ACE
34 traumatic brain injury 31.0 S100B ENO2
35 muscular dystrophy 31.0 TRDN TNNT2 RYR2 MYH7 CKB ACE
36 peripartum cardiomyopathy 31.0 SCN5A MYH7 ACE
37 dilated cardiomyopathy 30.9 TRDN TNNT2 SCN5A RYR2 PLN MYH7
38 sinoatrial node disease 30.9 SCN5A RYR2 ANK2
39 atrial heart septal defect 30.8 TNNT2 SCN5A MYH7 ACE
40 long qt syndrome 13 30.8 SCN5A ANK2 AKAP9
41 hemiplegia 30.8 S100B ENO2 DSP
42 atrial fibrillation 30.8 TNNT2 SCN5A RYR2 MYH7 MYBPC3 ANK2
43 aortic valve disease 2 30.7 TNNT2 MYH7 MYBPC3 ACE
44 long qt syndrome 2 30.6 TRDN SCN5A RYR2 CASQ2 CALM1 ANK2
45 tetralogy of fallot 30.6 TNNT2 SCN5A ENO2 ACE
46 pericarditis 30.6 TNNT2 ENO2 ACE
47 long qt syndrome 3 30.6 SCN5A RYR2 ANK2 AKAP9
48 left ventricular noncompaction 30.5 TNNT2 SCN5A RYR2 MYH7 MYBPC3 DSP
49 noonan syndrome with multiple lentigines 30.5 TNNT2 SCN5A RYR2 MYH7 MYBPC3
50 neonatal hypoxic and ischemic brain injury 30.4 ENO2 CKB

Comorbidity relations with Cardiac Arrest via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Aortic Aneurysm Aortic Valve Disease 1
Bronchitis Cardiogenic Shock
Decubitus Ulcer Deficiency Anemia
Disseminated Intravascular Coagulation Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome Intermediate Coronary Syndrome
Kidney Disease Mitral Valve Disease
Ocular Motor Apraxia Peripheral Vascular Disease
Progressive Familial Heart Block, Type Ia Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Respiratory Failure
Sinoatrial Node Disease Third-Degree Atrioventricular Block
Tricuspid Valve Disease Ventricular Fibrillation, Paroxysmal Familial, 1

Graphical network of the top 20 diseases related to Cardiac Arrest:



Diseases related to Cardiac Arrest

Symptoms & Phenotypes for Cardiac Arrest

UMLS symptoms related to Cardiac Arrest:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Cardiac Arrest:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 ACE CASQ2 CYCS DSP MYBPC3 MYH7
2 muscle MP:0005369 9.23 CASQ2 DSP MYBPC3 MYH7 RYR2 SCN5A

Drugs & Therapeutics for Cardiac Arrest

Drugs for Cardiac Arrest (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4
Eplerenone Approved Phase 4 107724-20-9 150310 443872
5
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
6
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
7
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9
Zinc Approved, Investigational Phase 4 7440-66-6 32051
10
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
11
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Meperidine Approved Phase 4 57-42-1 4058
14
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
15
parecoxib Approved Phase 4 198470-84-7
16
Thrombin Approved, Investigational Phase 4
17
Cangrelor Approved Phase 4 163706-06-7 9854012
18
Ticagrelor Approved Phase 4 274693-27-5 9871419
19
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
21
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
22
Etomidate Approved Phase 4 33125-97-2 36339 667484
23
Sodium citrate Approved, Investigational Phase 4 68-04-2
24
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
25
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
26
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
27 Kava Approved, Investigational, Nutraceutical Phase 4 9000-38-8
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
29 GABA Modulators Phase 4
30 Dermatologic Agents Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Calamus Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Amoxicillin-Potassium Clavulanate Combination Phase 4
36 beta-Lactamase Inhibitors Phase 4
37 Epoetin alfa Phase 4 113427-24-0
38 Antipyretics Phase 4
39 Hematinics Phase 4
40 Pyrithione zinc Phase 4
41 Keratolytic Agents Phase 4
42 Antihypertensive Agents Phase 4
43 Sympatholytics Phase 4
44 Omega 3 Fatty Acid Phase 4
45 Sodium-Glucose Transporter 2 Inhibitors Phase 4
46
protease inhibitors Phase 4
47 HIV Protease Inhibitors Phase 4
48 Angiotensin-Converting Enzyme Inhibitors Phase 4
49 Antigen-Antibody Complex Phase 4
50 Ketorolac Tromethamine Phase 4

Interventional clinical trials:

(show top 50) (show all 1227)
# Name Status NCT ID Phase Drugs
1 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
2 Hyperinvasive Approach to out-of Hospital Cardiac Arrest Using Mechanical Chest Compression Device, Prehospital Intraarrest Cooling, Extracorporeal Life Support and Early Invasive Assessment Compared to Standard of Care. A Randomized Parallel Groups Comparative Study. "Prague OHCA Study" Unknown status NCT01511666 Phase 4
3 Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
4 Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts Unknown status NCT02341833 Phase 4 Sevoflurane
6 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
7 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
8 Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. Unknown status NCT02341729 Phase 4 ticagrelor
9 Comparing Heated Humidified High-flow Nasal Cannula Therapy and Nasal Continuous Positive Airway Pressure (nCPAP) Ventilation Methods for the Prevention of Extubation Failure in Preterm Infants Less Than 32 Weeks' Gestational Age: Randomized Clinical Trial Unknown status NCT02887846 Phase 4
10 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
11 A Randomised, Double-Blinded, Placebo-Controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone Unknown status NCT00401856 Phase 4 Eplerenone;Placebo
12 Safety and Efficacy of Intranasal Dexmedetomidine as a Sedative in Pediatric Dentistry: a Randomized, Double-blind Clinical Study Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
13 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
14 Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study) Completed NCT00392639 Phase 4
15 Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
16 Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER) Completed NCT00101881 Phase 4
17 Prophylactic Versus Clinically-driven Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest Completed NCT02899507 Phase 4 Amoxicillin-Clavulanic acid
18 Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
19 Clinical and Neurological Outcome With Two Different Cooling Methods (Invasive and Non-invasive) After Sudden Cardiac Arrest Completed NCT00843297 Phase 4
20 Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation Completed NCT02750462 Phase 4
21 Clinical Evaluation of Intraosseous and Intravenous Access for Cardiac Arrest Treatment in Emergency Ambulances In Singapore Completed NCT02088736 Phase 4
22 Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest Completed NCT01369732 Phase 4 recombinant human erythropoietin;saline
23 Interest for a Relative of Seeing Himself Proposing to Witness Resuscitation of a Family Member Victim of a Cardiac Arrest Completed NCT01009606 Phase 4
24 A Phased Prospective Clinical Study Comparing Controlled Therapeutic Hypothermia Post Resuscitation After Cardiac Arrest Using External and Internal Cooling to Standard Intensive Care Unit Therapy Completed NCT00827957 Phase 4
25 Trial Of Continuous Compressions Versus Standard CPR In Patients With Out-Of-Hospital Cardiac Arrest Completed NCT01372748 Phase 4
26 Out-of-Hospital Intubation in Emergency Conditions With Either Metal Single Use or Reusable Laryngoscope Blades : Impact on Intubation Difficulties Completed NCT00644722 Phase 4
27 Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary in Patients After Survived Cardiac Arrest? A Prospective Randomised Multi-centre Trial. Completed NCT00180362 Phase 4
28 Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial Completed NCT02678728 Phase 4 Dexmedetomidine;normal saline
29 Clinical Outcomes and Long Term Effects of Sodium-glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Failing Heart Patients With Implantable Cardioverter Defibrillator Undergoing Trans-catheter Ablation for Ventricular Arrhythmias. Completed NCT03977116 Phase 4 SLGT2;Placebo
30 IRIS - Immediate Risk-stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK) Completed NCT00157768 Phase 4
31 Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial Completed NCT00667043 Phase 4 remifentanil and propofol;fentanyl and midazolam
32 The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial Completed NCT00269243 Phase 4 Quinapril
33 Comparison of Topical Analgesic With Saline Rinses in Post Extraction Healing Among Hypertensive and Non-hypertensive Subjects Completed NCT02921165 Phase 4 analgesic mouth rinses (dissolved Aspirin);Normal saline rinses.
34 Effects of OctaplasLG® on Endothelial Integrity in Patients Undergoing Emergency Surgery for Thoracic Aortic Dissections - a Randomized, Controlled, Single-blinded Investigator-initiated Pilot Trial Completed NCT02253082 Phase 4 OctaplasLG®
35 Is There Any Effect of Meperidine on the Length of Duration of Labor? A Prospective Randomized Controlled Trial. Completed NCT01555671 Phase 4 Placebo;Meperidine
36 Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by Parecoxib or Ketorolac in Humans Completed NCT00785863 Phase 4 Remifentanil;Ketorolac and remifentanil;Parecoxib and remifentanil
37 Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan Completed NCT01221649 Phase 4
38 Clopidogrel Or Metoprolol in Myocardial Infarction Trial Completed NCT00222573 Phase 4 clopidogrel and metoprolol
39 Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital Completed NCT02416817 Phase 4
40 Effects of Treatment With Omacor for 6 Weeks on Preprandial and Postprandial Endothelial Function Following a High Fat Meal in Patients With Type 2 Diabetes Mellitus Completed NCT00328536 Phase 4 Omacor
41 Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement Completed NCT00711360 Phase 4
42 Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation: The PrePARE Trial Completed NCT03026777 Phase 4 intravenous crystalloid fluid, 500 mL
43 Restrictive vs. Liberal Oxygen Therapy for Trauma Patients. PILOT: The TRAUMOX Trial Completed NCT03491644 Phase 4 Titrated Oxygen;Liberal Oxygen
44 An Investigation Into the Effects of Intravenous Lipid Emulsion (ILE) on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol. Completed NCT02924454 Phase 4 metoprolol;intravenous lipid emulsion;Sodium chloride 0.9% solution - lipid emulsion dummy;Sodium chloride 0.9% solution - metoprolol dummy
45 Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study Completed NCT02062801 Phase 4 Ephedrine;Placebo
46 Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management Recruiting NCT03273075 Phase 4 Cangrelor;Placebo;Prasugrel;Ticagrelor
47 Comparison of the Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest: Multi-center, Double Blind, Randomized, Placebo-controlled Study Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
48 Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention Recruiting NCT04005729 Phase 4 Cangrelor 50 MG
49 Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial Recruiting NCT02643381 Phase 4 Etomidate;Ketamine
50 Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation (PREPARE II Trial) Recruiting NCT03787732 Phase 4 Fluid Bolus

Search NIH Clinical Center for Cardiac Arrest

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atropine
Atropine Sulfate
Calcium Chloride
Calcium gluceptate
Calcium Gluconate
CALCIUM GLUCONATE PWDR
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
Methylatropine nitrate
Racepinephrine Hydrochloride
Sodium Bicarbonate
SODIUM BICARBONATE PWDR

Cochrane evidence based reviews: heart arrest

Genetic Tests for Cardiac Arrest

Genetic tests related to Cardiac Arrest:

# Genetic test Affiliating Genes
1 Cardiac Arrest 29

Anatomical Context for Cardiac Arrest

MalaCards organs/tissues related to Cardiac Arrest:

40
Heart, Brain, Lung, Liver, Kidney, Testes, Spinal Cord

Publications for Cardiac Arrest

Articles related to Cardiac Arrest:

(show top 50) (show all 35398)
# Title Authors PMID Year
1
COVID-19 in cardiac arrest and infection risk to rescuers: A systematic review. 61 42
32325096 2020
2
International Liaison Committee on Resuscitation: COVID-19 consensus on science, treatment recommendations and task force insights. 42
32371027 2020
3
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). 42
32359771 2020
4
Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest. 54 61
19307814 2009
5
Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia. 61 54
19467754 2009
6
Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. 54 61
18954930 2009
7
Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. 54 61
19131859 2009
8
[Role of neuron specific enolase and S100 protein in evaluation of brain damage in patients resuscitated from cardiac arrest]. 61 54
18093437 2007
9
Biochemical markers (NSE, S-100, IL-8) as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation. 54 61
17482335 2007
10
Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. 54 61
17502328 2007
11
2006 Curt P. Richter award winner: Social influences on stress responses and health. 61 54
17590276 2007
12
Carnitine-acylcarnitine translocase deficiency in three neonates presenting with rapid deterioration and cardiac arrest. 61 54
17277394 2007
13
Oxidative stress reversibly inactivates myocardial enzymes during cardiac arrest. 54 61
16920803 2007
14
Cardiac ryanodine receptor gene (hRyR2) mutation underlying catecholaminergic polymorphic ventricular tachycardia in a Chinese adolescent presenting with sudden cardiac arrest and cardiac syncope. 61 54
17199967 2006
15
Allelic variants of SCN5A and risk of sudden cardiac arrest in patients with coronary artery disease. 54 61
16731473 2006
16
Identification of the growth arrest and DNA damage protein GADD34 in the normal human heart and demonstration of alterations in expression following myocardial ischaemia. 61 54
16337513 2006
17
Changes of cytoskeletal proteins in ischaemic brain under cardiac arrest and reperfusion conditions. 54 61
16823696 2006
18
Ability of neuron-specific enolase to predict survival to hospital discharge after successful cardiopulmonary resuscitation. 61 54
17175624 2006
19
Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study. 54 61
16978415 2006
20
Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. 54 61
15797275 2005
21
Pulmonary haemorrhage and cardiac dysfunction in a neonate with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. 61 54
15858970 2005
22
Up-regulation of a growth arrest and DNA damage protein (GADD34) in the ischaemic human brain: implications for protein synthesis regulation and DNA repair. 61 54
15541008 2004
23
[Stem cell mobilization after coronary artery bypass grafting]. 54 61
15253141 2004
24
Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. 54 61
14631087 2003
25
Spatial resolution of phospholipid scramblase 1 (PLSCR1), caspase-3 activation and DNA-fragmentation in the human hippocampus after cerebral ischemia. 54 61
12605885 2003
26
Sialic acid or troponin T to detect perioperative myocardial damage in patients undergoing elective coronary artery bypass grafting. 61 54
12419933 2002
27
Natural history of Brugada syndrome: insights for risk stratification and management. 61 54
11901046 2002
28
Variable expression of long QT syndrome among gene carriers from families with five different HERG mutations. 61 54
11844290 2002
29
Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. 54 61
11382525 2001
30
Apical hypertrophic cardiomyopathy due to a de novo mutation Arg719Trp of the beta-myosin heavy chain gene and cardiac arrest in childhood. A case report and family study. 54 61
10957787 2000
31
Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. 61 54
10436107 1999
32
Monitoring of extracellular aspartate aminotransferase and troponin T by microdialysis during and after cardioplegic heart arrest. 61 54
10754346 1999
33
Different intracellular compartmentations of cardiac troponins and myosin heavy chains: a causal connection to their different early release after myocardial damage. 61 54
9732976 1998
34
Creatine kinase-mb fraction and cardiac troponin T to diagnose acute myocardial infarction after cardiopulmonary resuscitation. 54 61
8890819 1996
35
Corticosteroid and immune responses to cardiac surgery. 61 54
8837293 1996
36
Creatine kinase and creatine kinase-MB release after nontraumatic cardiac arrest. 61 54
8610606 1996
37
[Hypoxic brain damage after prolonged cardiac arrest during anesthesia--changes in CT and serum NSE concentration]. 61 54
7933514 1994
38
Serum corticosteroid-binding globulin levels in children undergoing heart surgery. 61 54
8273117 1993
39
CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. 54 61
8509798 1993
40
Determinants of elevated creatine kinase activity and creatine kinase MB-fraction following cardiopulmonary resuscitation. 61 54
1582302 1992
41
Evaluation of hypoxic brain injury with spinal fluid enzymes, lactate, and pyruvate. 61 54
1541099 1992
42
Changes of neuron-specific enolase concentration in plasma after cardiac arrest and resuscitation. 54 61
1958265 1991
43
Public-access defibrillation and neurological outcomes in patients with out-of-hospital cardiac arrest in Japan: a population-based cohort study. 61
31862250 2020
44
GPs who volunteer to be first responders for out-of-hospital cardiac arrest: A qualitative study. 61
31686571 2020
45
Increased PINK1/Parkin-mediated mitophagy explains the improved brain protective effects of slow rewarming following hypothermia after cardiac arrest in rats. 61
32330551 2020
46
Clinical features and prognosis of patients with spontaneous coronary artery dissection. 61
32245641 2020
47
Predictive model of return of spontaneous circulation among patients with out-of-hospital cardiac arrest in Thailand: The WATCH-CPR Score. 61
32187434 2020
48
Gerard W. Ostheimer Lecture: What's New in Obstetric Anesthesia 2018. 61
32149754 2020
49
Targeted temperature management in cardiac arrest patients with a non-shockable rhythm: A national perspective. 61
32485327 2020
50
Spinal cord collateral flow during antegrade cerebral perfusion for aortic arch surgery. 61
31543306 2020

Variations for Cardiac Arrest

ClinVar genetic disease variations for Cardiac Arrest:

6 (show all 37) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PLN NM_002667.5(PLN):c.116T>G (p.Leu39Ter)SNV Pathogenic/Likely pathogenic 13637 rs111033560 6:118880200-118880200 6:118559037-118559037
2 DSP NM_004415.4(DSP):c.2821C>T (p.Arg941Ter)SNV Pathogenic/Likely pathogenic 180326 rs730880082 6:7577219-7577219 6:7576986-7576986
3 CACNB2 NM_201596.3(CACNB2):c.1642G>A (p.Gly548Ser)SNV Conflicting interpretations of pathogenicity 180290 rs730880059 10:18828312-18828312 10:18539383-18539383
4 DSG2 NM_001943.5(DSG2):c.1063G>A (p.Ala355Thr)SNV Conflicting interpretations of pathogenicity 191629 rs201046640 18:29110998-29110998 18:31531035-31531035
5 MYBPC3 NM_000256.3(MYBPC3):c.3392T>C (p.Ile1131Thr)SNV Conflicting interpretations of pathogenicity 42711 rs370890951 11:47354463-47354463 11:47332912-47332912
6 RBM20 NM_001134363.3(RBM20):c.2662G>A (p.Asp888Asn)SNV Conflicting interpretations of pathogenicity 43995 rs201370621 10:112581039-112581039 10:110821281-110821281
7 DSG2 NM_001943.5(DSG2):c.437G>T (p.Arg146Leu)SNV Conflicting interpretations of pathogenicity 44317 rs113451409 18:29101120-29101120 18:31521157-31521157
8 TTN NM_001267550.2(TTN):c.29230C>T (p.Arg9744Cys)SNV Conflicting interpretations of pathogenicity 46820 rs375266859 2:179571371-179571371 2:178706644-178706644
9 SCN5A NM_198056.2(SCN5A):c.559A>G (p.Thr187Ala)SNV Conflicting interpretations of pathogenicity 222801 rs869025517 3:38662386-38662386 3:38620895-38620895
10 SLMAP NM_007159.4(SLMAP):c.1918+1G>ASNV Uncertain significance 222824 rs869025527 3:57898429-57898429 3:57912702-57912702
11 ANK2 NM_001148.6(ANK2):c.5509G>A (p.Ala1837Thr)SNV Uncertain significance 222498 rs199527708 4:114275283-114275283 4:113354127-113354127
12 ANK2 NM_001148.6(ANK2):c.7458C>G (p.His2486Gln)SNV Uncertain significance 222502 rs776972443 4:114277232-114277232 4:113356076-113356076
13 ANK2 NM_001148.6(ANK2):c.7577C>T (p.Ser2526Leu)SNV Uncertain significance 222503 rs762909298 4:114277351-114277351 4:113356195-113356195
14 DSP NM_004415.4(DSP):c.2047G>A (p.Glu683Lys)SNV Uncertain significance 222574 rs775181391 6:7572218-7572218 6:7571985-7571985
15 AKAP9 NM_005751.4(AKAP9):c.1067A>T (p.Asp356Val)SNV Uncertain significance 222487 rs533277424 7:91630298-91630298 7:92000984-92000984
16 DSP NM_004415.4(DSP):c.7249G>T (p.Asp2417Tyr)SNV Uncertain significance 222585 rs760501352 6:7584744-7584744 6:7584511-7584511
17 DPP6 NM_130797.4(DPP6):c.1039G>A (p.Ala347Thr)SNV Uncertain significance 222554 rs770646362 7:154564555-154564555 7:154772845-154772845
18 AKAP9 NM_005751.4(AKAP9):c.11276C>T (p.Pro3759Leu)SNV Uncertain significance 222492 rs869025356 7:91732086-91732086 7:92102772-92102772
19 CACNB2 NM_201596.3(CACNB2):c.1594T>G (p.Ser532Ala)SNV Uncertain significance 222520 rs869025371 10:18828264-18828264 10:18539335-18539335
20 VCL NM_014000.2(VCL):c.1559G>A (p.Arg520Gln)SNV Uncertain significance 222888 rs757009736 10:75855429-75855429 10:74095671-74095671
21 MYOM1 NM_003803.3(MYOM1):c.3708C>A (p.Ser1236Arg)SNV Uncertain significance 222745 rs869025489 18:3100176-3100176 18:3100178-3100178
22 KCNJ8 NM_004982.4(KCNJ8):c.83G>C (p.Arg28Pro)SNV Uncertain significance 222678 rs768851540 12:21926468-21926468 12:21773534-21773534
23 HCN4 NM_005477.3(HCN4):c.2197G>A (p.Val733Ile)SNV Uncertain significance 222648 rs376631391 15:73616237-73616237 15:73323896-73323896
24 DSG2 NM_001943.5(DSG2):c.2188A>G (p.Thr730Ala)SNV Uncertain significance 222564 rs780650226 18:29122669-29122669 18:31542706-31542706
25 TRPM4 NM_017636.4(TRPM4):c.1069C>T (p.Arg357Trp)SNV Uncertain significance 222852 rs764690335 19:49675284-49675284 19:49172027-49172027
26 AKAP9 NM_005751.4(AKAP9):c.11378C>G (p.Ser3793Cys)SNV Uncertain significance 180266 rs730880044 7:91735039-91735039 7:92105725-92105725
27 RYR2 NM_001035.3(RYR2):c.13759A>C (p.Ile4587Leu)SNV Uncertain significance 180504 rs730880198 1:237955600-237955600 1:237792300-237792300
28 RYR2 NM_001035.3(RYR2):c.378T>A (p.Ser126Arg)SNV Uncertain significance 222783 rs869025507 1:237532902-237532902 1:237369602-237369602
29 SCN5A NM_001099404.1(SCN5A):c.5075T>C (p.Phe1692Ser)SNV Uncertain significance 222813 rs869025521 3:38592788-38592788 3:38551297-38551297
30 MYH6 NM_002471.3(MYH6):c.4713G>T (p.Lys1571Asn)SNV Uncertain significance 180427 rs730880151 14:23855770-23855770 14:23386561-23386561
31 DSP NM_004415.4(DSP):c.2260G>A (p.Glu754Lys)SNV Uncertain significance 180323 rs730880080 6:7574448-7574448 6:7574215-7574215
32 CACNB2 NM_201596.3(CACNB2):c.1206+3A>TSNV Uncertain significance 180291 rs200174877 10:18823159-18823159 10:18534230-18534230
33 AKAP9 NM_005751.4(AKAP9):c.1099G>A (p.Val367Met)SNV Likely benign 180260 rs138161478 7:91630330-91630330 7:92001016-92001016
34 ANK2 NM_001148.6(ANK2):c.6206G>A (p.Arg2069His)SNV Likely benign 180270 rs149645600 4:114275980-114275980 4:113354824-113354824
35 SCN5A NM_000335.5(SCN5A):c.1715C>A (p.Ala572Asp)SNV Benign/Likely benign 67683 rs36210423 3:38645378-38645378 3:38603887-38603887
36 DSC2 NM_024422.6(DSC2):c.1073C>T (p.Thr358Ile)SNV Benign/Likely benign 46160 rs139399951 18:28662896-28662896 18:31082930-31082930
37 CACNA2D1 NM_000722.4(CACNA2D1):c.2264G>C (p.Ser755Thr)SNV Benign/Likely benign 180288 rs151327713 7:81599241-81599241 7:81969925-81969925

Expression for Cardiac Arrest

Search GEO for disease gene expression data for Cardiac Arrest.

Pathways for Cardiac Arrest

Pathways related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 TNNT2 SCN5A RYR2 PLN MYH7 CALM1
2
Show member pathways
12.29 TRDN TNNT2 SCN5A RYR2 PLN MYBPC3
3
Show member pathways
12.25 TRDN RYR2 PLN CALM1
4
Show member pathways
12.22 RYR2 PLN CASQ2 CALM1
5
Show member pathways
12.07 TRDN RYR2 PLN CASQ2 CALM1
6
Show member pathways
11.9 TNNT2 RYR2 PLN MYH7 MYBPC3 ACE
7 11.59 TRDN TNNT2 RYR2 MYH7 CASQ2
8
Show member pathways
11.46 SCN5A CALM1 AKAP9
9 10.85 SCN5A RYR2 PLN DSP CASQ2 ANK2

GO Terms for Cardiac Arrest

Cellular components related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.33 TRDN TNNT2 SLC25A20 S100B PPA2 MYBPC3
2 cell GO:0005623 9.98 TRDN RYR2 PLN CKB CASQ2 CALM1
3 sarcolemma GO:0042383 9.7 SCN5A RYR2 ANK2
4 Z disc GO:0030018 9.65 SCN5A RYR2 MYH7 CASQ2 ANK2
5 sarcoplasmic reticulum GO:0016529 9.62 TRDN RYR2 PLN CASQ2
6 intercalated disc GO:0014704 9.58 SCN5A DSP ANK2
7 myosin filament GO:0032982 9.54 MYH7 MYBPC3
8 calcium channel complex GO:0034704 9.54 RYR2 CASQ2 CALM1
9 A band GO:0031672 9.51 MYBPC3 ANK2
10 sarcoplasmic reticulum lumen GO:0033018 9.49 TRDN CASQ2
11 cardiac myofibril GO:0097512 9.48 TNNT2 MYBPC3
12 junctional membrane complex GO:0030314 9.46 TRDN CASQ2
13 junctional sarcoplasmic reticulum membrane GO:0014701 9.33 TRDN RYR2 CASQ2
14 sarcoplasmic reticulum membrane GO:0033017 9.26 TRDN RYR2 PLN CASQ2
15 sarcomere GO:0030017 9.02 TNNT2 RYR2 MYH7 MYBPC3 CALM1

Biological processes related to Cardiac Arrest according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.97 TRDN SCN5A RYR2 CASQ2
2 muscle contraction GO:0006936 9.87 TRDN TNNT2 MYH7 CALM1
3 cellular calcium ion homeostasis GO:0006874 9.86 TRDN RYR2 PLN ANK2
4 regulation of cardiac conduction GO:1903779 9.79 TRDN RYR2 CASQ2
5 muscle filament sliding GO:0030049 9.76 TNNT2 MYH7 MYBPC3
6 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.7 TNNT2 MYH7 MYBPC3
7 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.69 SCN5A ANK2 AKAP9
8 striated muscle contraction GO:0006941 9.68 MYH7 CASQ2
9 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.68 PLN CALM1
10 heart contraction GO:0060047 9.67 TRDN ACE
11 negative regulation of ATPase activity GO:0032780 9.67 TNNT2 PLN
12 regulation of cardiac muscle contraction GO:0055117 9.67 RYR2 CALM1 ANK2
13 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.66 RYR2 DSP
14 regulation of membrane repolarization GO:0060306 9.66 CASQ2 AKAP9
15 cellular response to caffeine GO:0071313 9.65 RYR2 CASQ2
16 atrial cardiac muscle cell action potential GO:0086014 9.65 SCN5A ANK2
17 positive regulation of ryanodine-sensitive calcium-release channel activity GO:0060316 9.65 TRDN CALM1
18 ventricular cardiac muscle cell action potential GO:0086005 9.65 SCN5A RYR2 ANK2
19 response to methylmercury GO:0051597 9.64 S100B ANK2
20 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.64 TRDN RYR2
21 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.63 RYR2 ANK2
22 regulation of cardiac muscle cell membrane potential GO:0086036 9.63 TRDN PLN
23 regulation of release of sequestered calcium ion into cytosol GO:0051279 9.63 TRDN CASQ2 ANK2
24 regulation of cell communication by electrical coupling GO:0010649 9.62 TRDN CASQ2
25 regulation of heart rate by cardiac conduction GO:0086091 9.62 SCN5A DSP ANK2 AKAP9
26 positive regulation of potassium ion transmembrane transporter activity GO:1901018 9.61 ANK2 AKAP9
27 SA node cell action potential GO:0086015 9.61 SCN5A ANK2
28 regulation of cardiac muscle cell contraction GO:0086004 9.61 SCN5A PLN ANK2
29 membrane depolarization during SA node cell action potential GO:0086046 9.6 SCN5A ANK2
30 sarcoplasmic reticulum calcium ion transport GO:0070296 9.59 RYR2 ANK2
31 regulation of atrial cardiac muscle cell action potential GO:0098910 9.58 RYR2 ANK2
32 detection of calcium ion GO:0005513 9.58 RYR2 CASQ2 CALM1
33 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0010880 9.56 TRDN PLN CASQ2 CALM1
34 regulation of SA node cell action potential GO:0098907 9.55 RYR2 ANK2
35 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.55 RYR2 PLN CASQ2 CALM1 ANK2
36 Purkinje myocyte to ventricular cardiac muscle cell signaling GO:0086029 9.54 RYR2 CASQ2
37 negative regulation of ryanodine-sensitive calcium-release channel activity GO:0060315 9.54 TRDN CASQ2 CALM1
38 cardiac muscle contraction GO:0060048 9.43 TNNT2 SCN5A RYR2 MYH7 MYBPC3 CASQ2
39 regulation of heart rate GO:0002027 9.1 SCN5A RYR2 MYH7 CASQ2 CALM1 ANK2

Molecular functions related to Cardiac Arrest according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nitric-oxide synthase binding GO:0050998 9.26 SCN5A CALM1
2 titin binding GO:0031432 9.16 MYBPC3 CALM1
3 calcium-dependent protein binding GO:0048306 9.13 S100B CASQ2 CALM1
4 ion channel binding GO:0044325 9.1 TRDN SCN5A RYR2 CALM1 ANK2 AKAP9

Sources for Cardiac Arrest

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....